久旱逢甘露之-- 新抗生素

creationrevolution.com

研發抗生素已被藥廠將近被忘記嘅事情
2014年FDA也有4隻新藥可用
香港唔知幾時會有

原來Ceftarolin 已經係2010年嘅事, 事隔幾年才登陸香江, 也不算是什麼新葯

"The FDA approval of ceftolozane/tazobactam (Zerbaxa) signifies several significant milestones in the battle against antibiotic-resistant superbugs. IDSA applauds Cubist and other public and private industry enterprises dedicated to helping combat the rise of antibiotic-resistant bacteria ... for their efforts to mitigate the sharp decline in the development of new antibiotics."
 
Other antibiotics approved in 2014 include three new agents with activity against methicillin-resistant Staphylococcus aureus (MRSA), indicated for acute skin and soft tissue infections in adults:

• Tedizolid, available oral or IV, and active against Gram-positive bacteria including Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus Group (including Streptococcus inosus, Streptococcus intermedius, and Streptococcus constellatus), and Enterococcus faecalis.
• Dalbavancin, indicated for a similar antimicrobial spectrum as tedizolid, minus E. faecalis. Dalvance is available through the IV route only, but has the advantage of requiring only two 30-minute infusions one week apart.
• Oritavancin, with a similar antimicrobial spectrum as Sivextro, but given as a single IV dose to replace a 7-day course of vancomycin.